Cargando…

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study

BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pagliari, Maria Teresa, Rosendaal, Frits R., Ahmadinejad, Minoo, Badiee, Zahra, Baghaipour, Mohammad‐Reza, Baronciani, Luciano, Benítez Hidalgo, Olga, Bodó, Imre, Budde, Ulrich, Castaman, Giancarlo, Eshghi, Peyman, Goudemand, Jenny, Karimi, Mehran, Keikhaei, Bijan, Lassila, Riitta, Leebeek, Frank W. G., Lopez Fernandez, Maria Fernanda, Mannucci, Pier Mannuccio, Marino, Renato, Oldenburg, Johannes, Peake, Ian, Santoro, Cristina, Schneppenheim, Reinhard, Tiede, Andreas, Toogeh, Gholamreza, Tosetto, Alberto, Trossaert, Marc, Yadegari, Hamideh, Zetterberg, Eva M. K., Peyvandi, Flora, Federici, Augusto B., Eikenboom, Jeroen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305521/
https://www.ncbi.nlm.nih.gov/pubmed/35092343
http://dx.doi.org/10.1111/jth.15658
_version_ 1784752345859489792
author Pagliari, Maria Teresa
Rosendaal, Frits R.
Ahmadinejad, Minoo
Badiee, Zahra
Baghaipour, Mohammad‐Reza
Baronciani, Luciano
Benítez Hidalgo, Olga
Bodó, Imre
Budde, Ulrich
Castaman, Giancarlo
Eshghi, Peyman
Goudemand, Jenny
Karimi, Mehran
Keikhaei, Bijan
Lassila, Riitta
Leebeek, Frank W. G.
Lopez Fernandez, Maria Fernanda
Mannucci, Pier Mannuccio
Marino, Renato
Oldenburg, Johannes
Peake, Ian
Santoro, Cristina
Schneppenheim, Reinhard
Tiede, Andreas
Toogeh, Gholamreza
Tosetto, Alberto
Trossaert, Marc
Yadegari, Hamideh
Zetterberg, Eva M. K.
Peyvandi, Flora
Federici, Augusto B.
Eikenboom, Jeroen
author_facet Pagliari, Maria Teresa
Rosendaal, Frits R.
Ahmadinejad, Minoo
Badiee, Zahra
Baghaipour, Mohammad‐Reza
Baronciani, Luciano
Benítez Hidalgo, Olga
Bodó, Imre
Budde, Ulrich
Castaman, Giancarlo
Eshghi, Peyman
Goudemand, Jenny
Karimi, Mehran
Keikhaei, Bijan
Lassila, Riitta
Leebeek, Frank W. G.
Lopez Fernandez, Maria Fernanda
Mannucci, Pier Mannuccio
Marino, Renato
Oldenburg, Johannes
Peake, Ian
Santoro, Cristina
Schneppenheim, Reinhard
Tiede, Andreas
Toogeh, Gholamreza
Tosetto, Alberto
Trossaert, Marc
Yadegari, Hamideh
Zetterberg, Eva M. K.
Peyvandi, Flora
Federici, Augusto B.
Eikenboom, Jeroen
author_sort Pagliari, Maria Teresa
collection PubMed
description BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag. OBJECTIVE: To investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity. METHODS: European and Iranian type 3 patients were enrolled in the 3WINTERS‐IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients’ diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann‐Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges‐Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman’s rank correlation. RESULTS: Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2–2.7; P = .016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0–4.2; P = .054]). FVIII:C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778). CONCLUSIONS: An increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype.
format Online
Article
Text
id pubmed-9305521
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93055212022-07-28 Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study Pagliari, Maria Teresa Rosendaal, Frits R. Ahmadinejad, Minoo Badiee, Zahra Baghaipour, Mohammad‐Reza Baronciani, Luciano Benítez Hidalgo, Olga Bodó, Imre Budde, Ulrich Castaman, Giancarlo Eshghi, Peyman Goudemand, Jenny Karimi, Mehran Keikhaei, Bijan Lassila, Riitta Leebeek, Frank W. G. Lopez Fernandez, Maria Fernanda Mannucci, Pier Mannuccio Marino, Renato Oldenburg, Johannes Peake, Ian Santoro, Cristina Schneppenheim, Reinhard Tiede, Andreas Toogeh, Gholamreza Tosetto, Alberto Trossaert, Marc Yadegari, Hamideh Zetterberg, Eva M. K. Peyvandi, Flora Federici, Augusto B. Eikenboom, Jeroen J Thromb Haemost HAEMOSTASIS BACKGROUND: Type 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag. OBJECTIVE: To investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity. METHODS: European and Iranian type 3 patients were enrolled in the 3WINTERS‐IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients’ diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann‐Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges‐Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman’s rank correlation. RESULTS: Homozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2–2.7; P = .016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0–4.2; P = .054]). FVIII:C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778). CONCLUSIONS: An increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype. John Wiley and Sons Inc. 2022-02-22 2022-05 /pmc/articles/PMC9305521/ /pubmed/35092343 http://dx.doi.org/10.1111/jth.15658 Text en © 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle HAEMOSTASIS
Pagliari, Maria Teresa
Rosendaal, Frits R.
Ahmadinejad, Minoo
Badiee, Zahra
Baghaipour, Mohammad‐Reza
Baronciani, Luciano
Benítez Hidalgo, Olga
Bodó, Imre
Budde, Ulrich
Castaman, Giancarlo
Eshghi, Peyman
Goudemand, Jenny
Karimi, Mehran
Keikhaei, Bijan
Lassila, Riitta
Leebeek, Frank W. G.
Lopez Fernandez, Maria Fernanda
Mannucci, Pier Mannuccio
Marino, Renato
Oldenburg, Johannes
Peake, Ian
Santoro, Cristina
Schneppenheim, Reinhard
Tiede, Andreas
Toogeh, Gholamreza
Tosetto, Alberto
Trossaert, Marc
Yadegari, Hamideh
Zetterberg, Eva M. K.
Peyvandi, Flora
Federici, Augusto B.
Eikenboom, Jeroen
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title_full Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title_fullStr Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title_full_unstemmed Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title_short Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS‐IPS study
title_sort von willebrand factor propeptide and pathophysiological mechanisms in european and iranian patients with type 3 von willebrand disease enrolled in the 3winters‐ips study
topic HAEMOSTASIS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305521/
https://www.ncbi.nlm.nih.gov/pubmed/35092343
http://dx.doi.org/10.1111/jth.15658
work_keys_str_mv AT pagliarimariateresa vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT rosendaalfritsr vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT ahmadinejadminoo vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT badieezahra vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT baghaipourmohammadreza vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT baroncianiluciano vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT benitezhidalgoolga vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT bodoimre vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT buddeulrich vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT castamangiancarlo vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT eshghipeyman vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT goudemandjenny vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT karimimehran vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT keikhaeibijan vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT lassilariitta vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT leebeekfrankwg vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT lopezfernandezmariafernanda vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT mannuccipiermannuccio vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT marinorenato vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT oldenburgjohannes vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT peakeian vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT santorocristina vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT schneppenheimreinhard vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT tiedeandreas vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT toogehgholamreza vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT tosettoalberto vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT trossaertmarc vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT yadegarihamideh vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT zetterbergevamk vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT peyvandiflora vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT federiciaugustob vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy
AT eikenboomjeroen vonwillebrandfactorpropeptideandpathophysiologicalmechanismsineuropeanandiranianpatientswithtype3vonwillebranddiseaseenrolledinthe3wintersipsstudy